Deferasirox

Drug Profile

Deferasirox

Alternative Names: CGP-72670; Exjade; ICL-670; ICL-670A; Jadenu

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Novartis
  • Class Benzoic acids; Small molecules; Triazoles
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Iron overload
  • Phase II Myelodysplastic syndromes
  • Discontinued Malaria

Most Recent Events

  • 20 Dec 2016 Novartis plans a phase II JUPITER trial for Thalassemia in Lebanon, Iran, Egypt, Saudi Arabia, Morocco, Algeria, Thailand, Turkey and Australia (NCT02993224)
  • 01 Aug 2016 Novartis initiates phase III extension study for Iron overload (NCT02720536)
  • 03 May 2016 Novartis Pharmaceuticals completes a phase II trial in Iron overload in USA, United Kingdom, Austria, Argentina, France, Greece, Mexico, Russia, Saudi Arabia, United Arab Emirates, Spain, Germany, Thailand, Italy, Malaysia and Lebanon (PO) (NCT02125877)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top